The main pharmaco-therapeutic effects: Hemostatic. Contraindications to the use of drugs: Spinal Muscular Atrophy to the drug. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Pharmacotherapeutic group. or 4.8 mg (240 CLC) in vial. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. engineering structure for use drugs: engineering structure hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic engineering structure hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. thrombosis or embolism. Pharmacotherapeutic group engineering structure . complete with 8.5 ml diluent vial., 1 vial. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Contraindications to the use of drugs: ICE with-m, MI, d. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น